Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Neuropsychiatric MRI brain signatures fail reproducibility test
Small neuroimaging studies are unlikely to capture consistent anatomical changes related to conditions such as autism, schizophrenia and mood disorders, according to a new “wake-up call” study.
Neuropsychiatric MRI brain signatures fail reproducibility test
Small neuroimaging studies are unlikely to capture consistent anatomical changes related to conditions such as autism, schizophrenia and mood disorders, according to a new “wake-up call” study.
Three models, three routes to altered auditory processing, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 10 August.
Three models, three routes to altered auditory processing, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 10 August.
Optimized two-photon microscopy enables voltage imaging at multiple depths
The tool could reveal how information flows within and between cortical layers during neural processing.
Optimized two-photon microscopy enables voltage imaging at multiple depths
The tool could reveal how information flows within and between cortical layers during neural processing.